Arrowhead Pharmaceuticals/$ARWR
Arrowhead Pharmaceuticals shares fall after the company released interim Phase 1/2a ARO-DIMER-PA data, with investors apparently unimpressed despite reported PCSK9 and APOC3 reductions.
11 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Ticker
- $ARWR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 711
- Headquarters
- Pasadena, United States
- Website
- arrowheadpharma.com
ARWR Metrics
BasicAdvanced
$10B
-
-$2.28
1.29
-
Price and volume
Market cap
$10B
Beta
1.29
52-week high
$95.49
52-week low
$28.48
Average daily volume
1.4M
Financial strength
Current ratio
5.899
Quick ratio
5.706
Long term debt to equity
2.856
Total debt to equity
2.96
Interest coverage (TTM)
-2.45%
Profitability
EBITDA (TTM)
-200.635
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-47.79%
Operating margin (TTM)
-33.82%
Effective tax rate (TTM)
-7.95%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-8.10%
Return on equity (TTM)
-55.21%
Valuation
Price to revenue (TTM)
14.827
Price to book
21.43
Price to tangible book (TTM)
21.69
Price to free cash flow (TTM)
-132.162
Free cash flow yield (TTM)
-0.76%
Free cash flow per share (TTM)
-0.535
Growth
Revenue change (TTM)
16.85%
Earnings per share change (TTM)
100.62%
3-year revenue growth (CAGR)
37.74%
10-year revenue growth (CAGR)
128.73%
3-year earnings per share growth (CAGR)
10.23%
10-year earnings per share growth (CAGR)
4.93%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
Analyst projections of the future price of Arrowhead Pharmaceuticals stock.
Bulls say / Bears say
Plozasiran produced strong Phase 3 results in severe hypertriglyceridaemia: triglycerides fell 79% and 81% in SHASTA-3 and SHASTA-4, while acute pancreatitis events fell 78% in pooled analysis. Both trials met their primary and all pre-specified secondary endpoints. (Arrowhead Pharmaceuticals)
REDEMPLO is moving beyond a single-market launch, with authorisations in the US, Canada, China, Australia and the EU. Arrowhead also reported that prescriptions more than doubled quarter on quarter, suggesting early commercial traction before the planned broader indication. (Arrowhead Pharmaceuticals, Yahoo Finance)
Arrowhead is turning its RNAi platform into partnered revenue and future optionality: Madrigal paid $25 million upfront for ARO-PNPLA3, with up to $975 million in development, regulatory and sales milestones plus tiered royalties. The deal could reduce the amount of each programme that Arrowhead must fund alone. (Morningstar)
The company remains deeply loss-making while investing heavily: fiscal third-quarter net loss was $194.3 million and research and development spending was $198.2 million. Arrowhead had substantial liquid resources, but also reported $682.7 million of convertible notes and an $181.4 million credit facility, leaving less room for execution errors. (Morningstar)
Commercial revenue is still small relative to the headline total: REDEMPLO sales were reported at roughly $2.4 million in the quarter, while the $75.3 million total was driven mainly by licensing and collaboration income. That leaves the investment case dependent on successful reimbursement and uptake in larger indications. (Simply Wall St, Arrowhead Pharmaceuticals)
Positive SHASTA results do not yet equal approval or revenue: Arrowhead still plans to file the supplemental application by the end of 2026, while the Phase 3 YOSEMITE trial is not expected to finish until mid-2027 and any filing depends on successful results. Delays, an unfavourable label or weaker later-stage data could defer the next major value inflection. (Arrowhead Pharmaceuticals, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Business Wire19 hours ago
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Business Wire2 weeks ago
Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
MarketBeat2 weeks ago
Funds containing ARWR
AllUSDEURGBP
Fund name | Fund size | $ARWR weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.19% |
iShares Healthcare Innovation£DRDR | £1B | 1.19% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.76% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.76% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.